cervical cancer
Conditions
Interventions
experiment group:TP*4 cycle
Sponsors
the Second Affiliated Hospital of Fujian Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed, pathological confirmed cervical cancer; 2. Aged 18-70 years; 3. HPV DNA positive pretretment; 4. Local advanced Figo stage IIA2-IVA; 5. No clinical or radiological evidence of diastant metastasis at diagnosis; 6. CR at 1 month after completion of RT or CCRT; 7. Detectable HPV DNA at 1 month after completion of RT or CCRT; 8. ECOG 0 or 1; 9. Patients must have adequate organ and marrow function as defined below: leukocytes >3,000/L; absolute neutrophil count >1,500/L; platelets >100,000/L; total bilirubin 50 ml/min; 10. Have given written informed consent, prior to pre-study screening, with the understanding that consent may be withdrawn at any time without prejudice.
Exclusion criteria
Exclusion criteria: 1. Pregnant or breast-feeding; 2. Second primary malignancy in last 5 years (except adequately treated basal cell carcinoma of the skin); 3. More that 12 weeks after completion of primary radiotherapy; 4. Had received prior adjuvant chemotherapy; 5. Other serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;local-regional failure free survival;distant failure free survival;toxicity;the influence of residual HPV DNA on survival of cervical cancer received RT or CCRT; | — |
Countries
China
Contacts
Public ContactYanhong Wang
the Second Affiliated Hospital of Fujian Medical University
Outcome results
None listed